BACKGROUND: Patients with type 2 diabetes mellitus (DM) are at increased risk for colorectal adenomas and cancer because of endogenous hyperinsulinemia. Exogenous insulin therapy has been associated with higher colorectal cancer incidence. The aim of this study was to evaluate the association between exogenous insulin therapy and adenoma formation, accounting for duration of therapy and location and stage of the adenoma. METHODS: We conducted a cross-sectional study of patients with type 2 diabetes between the ages of 50 and 80 years who completed full colonoscopies. Cases were patients with any adenoma on index colonoscopy. Patients without any adenoma composed the control group. Multivariable logistic regression was used to calculate odds ratios (OR) and associated confidence intervals (CI). RESULTS: Compared with the controls, case patients (n = 196) did not have a significantly increased odds of insulin exposure, when exposure was defined as 12 months or more of insulin use compared with no insulin. However, the odds of insulin exposure among the cases was significantly increased when exposure was defined as 18 months or more (OR 1.6, 95% CI 1.1-2.5), 24 months or more (OR 1.7, CI 1.1-2.6), and 36 months or more (OR 2.0, 95% CI 1.2-3.4) of insulin use (test for trend P = 0.05). A similar trend in insulin exposure was seen among type 2 diabetics with advanced adenomas. Adenoma location was not significantly affected by insulin therapy. CONCLUSIONS: Chronic insulin therapy is associated with increased risk of colorectal adenomas in patients with type 2 diabetes. IMPACT: Diabetes patients receiving insulin may need more stringent colon cancer screening. 2012 AACR
BACKGROUND:Patients with type 2 diabetes mellitus (DM) are at increased risk for colorectal adenomas and cancer because of endogenous hyperinsulinemia. Exogenous insulin therapy has been associated with higher colorectal cancer incidence. The aim of this study was to evaluate the association between exogenous insulin therapy and adenoma formation, accounting for duration of therapy and location and stage of the adenoma. METHODS: We conducted a cross-sectional study of patients with type 2 diabetes between the ages of 50 and 80 years who completed full colonoscopies. Cases were patients with any adenoma on index colonoscopy. Patients without any adenoma composed the control group. Multivariable logistic regression was used to calculate odds ratios (OR) and associated confidence intervals (CI). RESULTS: Compared with the controls, case patients (n = 196) did not have a significantly increased odds of insulin exposure, when exposure was defined as 12 months or more of insulin use compared with no insulin. However, the odds of insulin exposure among the cases was significantly increased when exposure was defined as 18 months or more (OR 1.6, 95% CI 1.1-2.5), 24 months or more (OR 1.7, CI 1.1-2.6), and 36 months or more (OR 2.0, 95% CI 1.2-3.4) of insulin use (test for trend P = 0.05). A similar trend in insulin exposure was seen among type 2 diabetics with advanced adenomas. Adenoma location was not significantly affected by insulin therapy. CONCLUSIONS:Chronic insulin therapy is associated with increased risk of colorectal adenomas in patients with type 2 diabetes. IMPACT: Diabetespatients receiving insulin may need more stringent colon cancer screening. 2012 AACR
Authors: Ann G Zauber; Sidney J Winawer; Michael J O'Brien; Iris Lansdorp-Vogelaar; Marjolein van Ballegooijen; Benjamin F Hankey; Weiji Shi; John H Bond; Melvin Schapiro; Joel F Panish; Edward T Stewart; Jerome D Waye Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: D K Rex; G A Lehman; T M Ulbright; J J Smith; D C Pound; R H Hawes; D J Helper; M J Wiersema; C D Langefeld; W Li Journal: Am J Gastroenterol Date: 1993-06 Impact factor: 10.864
Authors: Sarah F Andres; James G Simmons; Amanda T Mah; M Agostina Santoro; Laurianne Van Landeghem; P Kay Lund Journal: J Cell Sci Date: 2013-10-14 Impact factor: 5.285
Authors: Sander de Kort; Mariëlle We Bouwens; Matty P Weijenberg; Maryska Lg Janssen-Heijnen; Adriaan P de Bruïne; Robert Riedl; Ad Am Masclee; Silvia Sanduleanu Journal: United European Gastroenterol J Date: 2016-08-09 Impact factor: 4.623
Authors: M Agostina Santoro; R Eric Blue; Sarah F Andres; Amanda T Mah; Laurianne Van Landeghem; P Kay Lund Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-08-06 Impact factor: 4.052